Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice
[Chicago, Illinois] – Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics are pleased to announce a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice. This collaboration combines Nucleai’s AI-powered spatial biology technology with Mayo’s […]
Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials
CHICAGO–(BUSINESS WIRE)–Nucleai, a leader in AI-powered spatial biology, and Adlai Nortye, a global biopharmaceutical company focused on developing innovative immuno-oncology therapies, today announced a strategic partnership to identify, validate and test novel H&E-based biomarkers across Adlai Nortye’s Phase 2 and 3 clinical trials. The collaboration will initially focus on identifying subjects that could derive benefit […]
Nucleai Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts
TEL AVIV, Israel – May 24, 2023 – Nucleai, a leader in AI-powered spatial biology, today announced the two key appointments to its leadership team and scientific advisory board. Pharmaceutical industry veteran Oscar Puig, Ph.D. has been named the VP of Transitional Medicine & Diagnostics at Nucleai, while Suzana Couto, the Head of Pathology at […]
Spatial Multiomics Powers Pathology Prediction
Spatial multiomics, still in its discovery phase, can mean different things to different people. It typically denotes the visualization of transcriptomic and proteomic data in the context of tissue architecture, either directly on the same section or on serial sections that are integrated computationally. Spatial multiomics may eventually grow to encompass lipids, glycans, metabolites, epigenetic […]
Nucleai Expands Scientific Advisory Board with Oncology Industry Luminary Dr. Julian Adams
Nucleai, an AI-powered spatial biology leader, announced that Dr. Julian Adams has joined its scientific advisory board. Dr. Adams brings his more than 35 years of experience in oncology research and development to his role as an advisor to Nucleai, which is recognized as one of the top startups to watch in the spatial biology […]
Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development
Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development. Nucleai will present new […]
Nucleai Hopes to Engage Pharma on Next-Gen Immunotherapies With Proof-of-Concept AI-Based Biomarker
NEW YORK –Nucleai researchers investigated whether, by using spatial biology to analyze interactions between the immune system and tumor microenvironment, it is possible to find biomarkers predictive of sensitivity to immuno-oncology drugs. In a retrospective multi-center study conducted in the US and Israel, where the firm is based, Nucleai analyzed biopsy slides and clinical outcomes […]
Israel: An Untapped Biotech Investment Opportunity
With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem on the heels of a renowned high-tech industry. Much more than just the iconic Teva Pharmaceuticals, venture capitalists would do well to pay attention to the innovation stemming from this largely unmined investment opportunity. “Everything about it is about innovation,” said Michael […]
Nucleai, Propath Partnership Paves Way for Spatial Oncology Biomarkers
Spatial biology specialists Nucleai and Propath UK have announced a partnership to develop and validate an immunofluorescence assay focused on 30 immuno-oncology protein targets that could inform the development of novel oncology biomarkers and companion diagnostics. Dr Ken Bloom, head of Pathology at Nucleai, explained that spatial biology—the study of tissues within their multidimensional context—“is considered a new frontier and […]
Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel
Propath UK, Europe’s leading CRO for spatial biology, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking spatial biology insights from pathology data, announce their collaboration to develop and validate a 30-plex immunofluorescence (IF) panel focused on protein targets relevant to immuno-oncology. For our pharmaceutical and biotechnology partners, this groundbreaking panel, in […]
